ReviewDrug design, development and therapy2026
Natural Compounds Targeting Coronary Microvascular Dysfunction: Mechanisms and Beyond.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary microvascular dysfunction (CMD) is increasingly recognized as a major public health burden, independently contributing to myocardial ischemia, adverse cardiovascular events, and elevated healthcare costs. Its pathophysiology is multifactorial, involving endothelial dysfunction, microthrombosis, and metabolic disturbances. Natural compounds, owing to their multi-target effects and favorable safety profiles, have emerged as promising candidates for CMD intervention. This narrative review systematically consolidates current evidence on the key molecular targets and regulatory mechanisms through which natural compounds preserve microvascular homeostasis. It also highlights shared pathological pathways between CMD and other cardiovascular diseases to support cross-disease therapeutic translation. By integrating these findings, this review aims to establish a theoretical foundation for future preclinical and clinical applications of natural compounds in CMD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.